Incidence and survival of multiple myeloma: a population‐based study of 10 524 patients diagnosed 1982–2017

Abstract

Summary Population‐based studies from high‐quality nationwide cancer registries provide an important alternative to clinical trials in the assessment of the impact of modern myeloma treatment. Based on data from the Cancer Registry of Norway, we investigated trends in incidence and relative survival (RS) for 10 524 patients in three age groups diagnosed between 1982 and 2017. Nationwide myeloma drug consumption statistics were obtained from the Norwegian Institute of Public Health. Patients aged <65 years had a steady increase in both 5‐ and 10‐year RS across all calendar periods from 1982. For patients aged 65–79 years, RS was stable until the calendar period 1998–2002, followed by an improvement in both 5‐ and 10‐year RS. The 5‐year RS for patients aged ≥80 years also increased significantly between the first and the last calendar period. In conclusion, we demonstrate a significant improvement in 5‐year RS in all age groups. Improved RS in patients aged ≥80 years at the time of diagnosis is only rarely described in other population‐based studies. For patients aged ≥65 years, the improvement in RS coincides with the introduction of modern drugs, whereas patients aged <65 years had an ongoing improvement before the introduction of autologous stem‐cell transplant.

Belantamab Mafodotin in Combination with Novel Agents in Relapsed/refractory Multiple Myeloma: DREAMM-5 Study Design

“…Through the use of immunomodulatory agents and proteasome inhibitors (PI) sequentially with autologous stem-cell transplantation and significant improvements in supportive care strategies, the median overall survival (OS) of patients with MM has almost doubled in the past two decades, with comparable improvements also seen in the transplant-ineligible population [4][5][6][7]. In addition, the introduction of anti-CD38 monoclonal antibodies (mAbs), such as daratumumab, and antisignaling lymphocytic activation molecule family member seven antibody elotuzumab, used alone or in combination with immunomodulatory agents and PIs, has further enhanced response and improved survival rates in patients with MM, including in those with relapsed or refractory MM (RRMM) [6,[8][9][10].…”

Management of Adverse Events and Supportive Therapy in Relapsed/Refractory Multiple Myeloma

“…Complications of MM are not only a source of morbidity, but they are the leading cause of death [ 2 ]. Indeed, advances in supportive therapies along with the integration of novel strategies in the treatment landscape of MM have significantly contributed to the improved survival observed in the recent decade [ 3 , 4 , 5 ].…”

Patterns of previous and secondary malignancies in patients with multiple myeloma

“…Population‐based studies show that relative survival in MM patients has improved substantially since the 1990s 1,2 . As patients are living longer with their disease, the awareness concerning secondary primary malignancies (SPM) has been raised.…”